Analysts Set Royalty Pharma plc (NASDAQ:RPRX) PT at $41.60

Shares of Royalty Pharma plc (NASDAQ:RPRX) have earned a consensus rating of “Buy” from the six research firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $41.60.

RPRX has been the topic of several research analyst reports. Citigroup restated a “buy” rating on shares of Royalty Pharma in a research report on Friday. TD Cowen raised shares of Royalty Pharma to a “strong-buy” rating in a research note on Tuesday, December 24th.

Royalty Pharma Price Performance

Shares of NASDAQ RPRX opened at $31.37 on Friday. The firm has a market capitalization of $18.08 billion, a PE ratio of 21.63, a price-to-earnings-growth ratio of 2.31 and a beta of 0.47. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44. Royalty Pharma has a fifty-two week low of $24.05 and a fifty-two week high of $34.20. The stock’s 50-day simple moving average is $32.44 and its 200-day simple moving average is $28.86.

Royalty Pharma (NASDAQ:RPRX) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. As a group, equities research analysts forecast that Royalty Pharma will post 4.49 EPS for the current fiscal year.

Royalty Pharma Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 10th. Investors of record on Friday, February 21st were paid a dividend of $0.22 per share. The ex-dividend date of this dividend was Friday, February 21st. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.21. This represents a $0.88 annualized dividend and a yield of 2.81%. Royalty Pharma’s dividend payout ratio (DPR) is 60.69%.

Institutional Trading of Royalty Pharma

A number of institutional investors and hedge funds have recently made changes to their positions in RPRX. Brooklyn Investment Group raised its holdings in shares of Royalty Pharma by 1,006.9% during the fourth quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 876 shares during the last quarter. Allworth Financial LP raised its stake in shares of Royalty Pharma by 417.6% in the 4th quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 877 shares in the last quarter. Riverview Trust Co lifted its holdings in shares of Royalty Pharma by 3,953.3% in the fourth quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 1,186 shares during the period. Fifth Third Bancorp boosted its position in shares of Royalty Pharma by 187.1% during the 4th quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 997 shares in the last quarter. Finally, Blue Trust Inc. boosted its holdings in Royalty Pharma by 31.3% during the fourth quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 376 shares in the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.